Summary

Hepatitis C virus (HCV) infection is a major public health problem in the European
Union (EU)
for action in order to make HCV and its elimination in Europe an explicit public health priority, to ensure that patients, civil society groups and other relevant stakeholders will be directly involved in developing and implementing HCV elimination strategies, to pay particular attention to the links between hepatitis C and social marginalization and to introduce a European Hepatitis Awareness Week.
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Chronic infection with HCV has a high prevalence and is the seventh leading cause of death worldwide. It was initially estimated that up are expensive, they will be cost-effective in the long term by reducing the costs of treating decompensated cirrhosis, hepatocellular cancers and the number of liver transplantations.
However, HCV infection presents specific challenges that require holistic, patient-centred and health system-wide approaches that address awareness, prevention, care and treatment through the joint collaboration of health providers, patients and stakeholders. In the current context faced by many European countries, with threats to the fiscal security of health systems and neglect of marginalized populations, putting HCV on the health policy agenda is even more crucial.
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A question that often arises is why HCV infection continues to be a major public health problem in Europe, with a prevalence seven times greater than that of HIV. 13 The answer lies in the facts that HCV patients often have no symptoms for the first 20-30 years of infection, and surveillance of HCV is weak across many EU countries. 14 Also, the burden of HCV is disproportionately present in marginalized populations including PWID, prisoners, migrants and the homeless. Systematic screening policies are lacking, and it is not clear which are the most cost-effective methods for recruiting these hard-to-reach populations into testing, care and treatment programmes.
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The key issues for addressing HCV in Europe are the following.
| A "silent" epidemic
The undetected spread of HCV is one of the most important chal- 19, 20 Therefore, several recent international guidelines recommend HCV treatment in PWID. 21, 22 Nevertheless, PWID face various barriers to treatment, including access to testing for HCV, lack of awareness of HCV infection and discrimination, which are strongly linked with the criminalization of drug use, memories of painful interferonbased treatments, police brutality, lack of awareness of the existence of DAAs, all of which delay entry into effective treatment. 
| Burden on health systems
The cost of HCV to European health systems is significant. Costs to health systems include ongoing treatment of cirrhosis, HCC and end-stage renal disease, among others, which amount to an enormous expenditure by European countries. 10 In a survey including five European countries, the estimated direct and indirect costs in patients with chronic hepatitis C were 76% and 65%, respectively, higher than people without hepatitis C in 2010. 24 HCV is also related to a loss of productivity among those infected, when patients are unable to fully participate at their workplaces and in society.
| Unnecessary burden on quality of life
Eliminating HCV is not just an urgent financial matter, it is a question of human rights, as living with HCV greatly impacts quality of life for families and communities. Aside from being a practical possibility, for the patient a cure is not only possibly life-saving, but also life-changing. 4 Although the majority of cases have not yet been identified, risk groups are well-known and the tools and means for eliminating the disease are available with appropriate commitment from governments, the pharmaceutical industry, patients, health providers and others stakeholders.
| Improving coordination among member states
Although there has been a call to action among member states, including ongoing discussions and initiatives among stakeholders in conjunction with patient associations like ELPA, there is still a general lack of coordination among member states. Coordination must happen at the EU and national levels with the wider involvement of stakeholders including policy makers, nongovernmental organizations, patients, the health sector and others.
| Engaging stakeholders
It is widely believed that the current opportunity to eliminate HCV will require the engagement of partners around Europe to link research, services, health providers and policy makers. Key focus areas for stakeholder engagement include: (i) access to affordable/ free treatment and care (ii) scale-up of harm reduction by connecting marginalized groups to needed services and addressing barriers like stigma and discrimination, as well as laws that criminalize drug use and (iii) the full involvement of the affected communities in these processes. 25 Indeed, advocacy groups and associations are working with stakeholders to advance elimination by creating and disseminating HCV management guidelines, raising awareness, collaborating with ECDC, WHO, EMCDDA and other groups but an integral approach on national and local level often is missing. In particular, EASL has created, updated and disseminated guidelines for the management of hepatitis C, and also organizes the annual International Liver
Congress, gathering more than ten thousand attendees each year. In addition, EASL has emphasized the need for future research regarding better clarification of: (i) epidemiological data for HCV infection in the general population and specific patients groups in the EU; (ii) reinfection rates following effective antiviral therapy in PWID; (iii) ideal access to anti-HCV treatments at the national levels; and d) the public health impact of anti-HCV therapy on specific group of patients.
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A key challenge to HCV elimination in Europe is the lack of reliable estimates of the burden of disease. Knowing the true burden of disease and the profile of those infected is necessary in order to design programmes and policies to scale-up prevention and treatment. The burden of disease estimates is also necessary for estimating the cost that these efforts entail for European health systems.
In an effort to produce more reliable prevalence estimates, the Center for Disease Analysis (CDA) has been visiting nearly every EU country in order to assess the HCV disease burden through expert consultation and modelling. CDA estimates show 3.6 million viremic infections in European Union, with only 1.2 million cases diagnosed ( Figure 1A ), 1 million treated and 500 000 cured. Overall, 
there is a viremic prevalence of around 0.7% (with one-third of infections already diagnosed), which was less than expected.
However, it should be emphasized that there is a great geographical variation regarding prevalence (range: 0.1%-2.6%) and diagnosis rates (from 10% to almost 90%; Figure 2 ). Interestingly, most of the patients infected in Europe are between 45 and 60 years old (with a median age of 54 years), indicating a possible target birthcohort group for screening programmes ( Figure 1B) . 32, 33 Similarly, HCV treatment rates vary dramatically across the EU (ranging from 0.6% to 10.2%) and unfortunately in many countries there is a great discordance between prevalence rates and treatment rates ( Figure 2 Figure 3A) . However, if we use the more effective new DAAs in those with more than moderate (>F2) fibrosis, HCV infections will decline by 70%, while HCV-related morbidity and mortality will decrease by 45%-55%
( Figure 3B ). Finally, based on the elimination scenario (ie, expand screening to find infected individuals to treat all patients up to age of 70 years with DAAs irrespectively of fibrosis stage, starting in 2017), HCV infections will decline 90% by 2030 and 95% by 2035, while liver-related diseases will decline 55% by 2030 and 70% by 2035 ( Figure 3C ). Interestingly, this policy seems to be more cost-effective than the status quo and this is common to all countries irrespective of their average incomes. Nevertheless, although negotiation of drug prices is important, the central issue for HCV elimination is how to pay for it now in order to ensure cost saving in the long run.
Thus, it is feasible to eliminate HCV infection in the EU but treatment has to be increased to 6%-10% of total infections (coupled with active screening), to reduce new infections, while screening and treatment have to encompass all HCV-infected individuals irrespectively of fibrosis stage, as most new infections occur among younger individuals who have mild to no fibrosis (F0 or F1). In addition, in order to reduce liver-related deaths, eligibility has to increase to older patients (currently, the median age in the EU is 54 years, and half of the HCV-infected population will be above 65 years in 11 years). However, it should be emphasized that because treatments are curative, the number of treated patients and the associated costs is finite. Thus, treatment of HCV is cost saving, but a mechanism is needed to help countries manage the initial increase in spending to achieve HCV elimination.
| THE FIR S T G LOBAL HEPATITIS S TR ATEGY
Elimination requires EU and regional leadership, according to WHO. threat within the framework of universal coverage rather than as a specific disease intervention. To this end, the Hepatitis Strategy focuses on stronger prevention and health system efforts with five strategic directions including the following:
(i) information for focus and accountability, (ii) interventions, (iii) quality and equitable delivery, (iv) financing and (v) innovation.
While reducing hepatitis as a health threat does not necessarily imply eradication, elimination is achievable through a scale-up of treatment and prevention services. In order to eliminate hepatitis as a health threat, the Strategy sets the targets of a 90% reduction in new cases of chronic HBV and HCV in addition to a 65% reduction in deaths. Some Strategy interventions have already made significant progress, but others represent challenges.
For example, to reach these targets, 90% of those living with hepatitis B and C need to be diagnosed and 90% of those put on treatment, which requires an enormous scale-up in testing and treatment.
Given the current European political and social contexts, this scale-up is only possible through the adoption of a public health approach, focusing on innovation and committed partnerships with government, civil society and the private sector, in addition to concrete and tailored actions by European national governments. All of this needs to be translated into national action plans, which will be discussed at the next World Health Assembly.
| THE COS T OF H C V ELIMINATI ON
The cost of treating the disease is a serious obstacle to the elimina- Thus, resources spent on HCV provide good value for money, given that high initial annual spending will give way to decreased costs in the medium term. 34, 35 One potential option suggested for obtaining funds needed to expand HCV treatment is the creation of a European Hepatitis Fund. 26 Such a fund would receive money from donors and serve as a platform for negotiating prices with drug companies and managing cash flow.
The Hepatitis Fund would serve to help countries manage the initial increase in health spending needed to combat the disease, with the benefit that later costs can be recouped through health savings.
| CURRENT AC TI ON ON H C V AT THE EU LE VEL
At the EU level, action on HCV is underway by the EC, which coordinates the response of member states to public health threats.
Action includes engaging the EU Health Program, where some viral hepatitis activities are financed, particularly with regard to improving access to testing and access to care.
Another European action includes the EU HIV/AIDS Action Plan 2014-2016, which treats viral hepatitis as a co-infection, and the work of EU agencies that provide independent scientific advice. The EC has organized country visits to member states, and agencies such as ECDC and EMCDDA play a role in surveillance.
At the same time, the European Medicines Agency approved nine new medicinal products through accelerated approval processes in 2014-2017. 31 The agency is also initiating a new mechanism whereby member states can purchase together to obtain better prices and conditions (joint procurement). Health and technology assessment can also benefit from being carried out in a common way among member states. In addition, they are referred directly to a specialist with appointments no longer than six weeks for appropriate treatment options in line with the latest clinical guidelines. Finally, it is important to monitor infected patients in order to prevent the development of cirrhosis and HCC.
| EU HE ALTH SYS TEMS SUS TAINAB ILIT Y
Treatment. It is important to ensure open dialogue between pa-
tients and healthcare professionals including about the new HCV drugs. 36, 37 The latter should be offered without restrictions in all infected patients under the care of specialists, and in community settings wherever this is possible and safe according to the EASL guidelines. 11 In addition, any HCV strategy should include prevention, diagnosis and treatment and should place patients at its core.
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There are many cases of good practices in HCV strategies for policies, prevention, screening and treatment across Europe, including
France, Germany, Netherlands, Portugal and Scotland Several countries have developed successful practices through political engagement, a commitment to research and the use of evidence to inform policies and programmes, and a concerted focus on the most marginalized groups at increased risk for HCV, including drug users and prison populations.
| France
In France, a country with an estimated viremic prevalence, diagnosis rate and treatment rate were 0.3%, 69% and 5.2%, respectively, in
2013
. 45 In addition, in 2014, of an estimated 74 000 undiagnosed HCV and HBV patients aged 18-80 years, 37% were 70-80 years old (ages 60-80 years were mostly women) and the majority of those 18-59 years old were men. 38, 40 Thus, the undiagnosed HCV population in France is mostly men under 70 years old. New French guidelines from 2016 emphasize a risk factor-based, targeted screening strategy in addition to population-based testing for HIV, HBV and HCV, focused on all 18-59 years old.
| Germany
The German Action Plan on Hepatitis, developed in 2013, includes recommendations for (i) better information for drug users, (ii) sterile or hygienic drug use and paraphernalia, (iii) recruiting more addicts into therapy and (iv) employing specially trained HCV nurses for patient monitoring. The plan is informed by research including the DRUCK study, a multi-site sero-behavioural survey which showed that the prevalence of HCV infection among drug users ranged between 42.3% and 75% and of HIV infection between 0% and 9.1%, 6% of HCV infected were HIV positive, while 83% of HIV infected were also HCV positive. 46, 47 Interestingly, only 19.4% had been ever successfully treated. The study showed frequent unsafe drug use, unknown infection status, gaps in knowledge about the means of transmission, low rates of HBV vaccination and imprisonment as an element of the risk profile, among others. In providing information on the hidden population of drug users, this study and others have helped to generate better knowledge of the population affected in order to inform hepatitis prevention efforts among drug users in Germany.
| Italy
In 2015, a survey based on testing and treatment claims identi- by 75% during 2015-2020 was approved as was the prioritization of therapy for those with moderate to severe liver disease; this approach was agreed in the context of the need to achieve optimal benefit from highly effective but costly drugs.
| Scotland
As the action plan had invested in robust monitoring systems, it has been possible to gauge the impact of this approach. Preliminary data indicate that the incidence of HCV-related decompensated cirrhosis is now on the decline and that Scotland is cautiously optimistic that the 2020 target will be reached. Subject to reductions in the cost of therapy, it is likely that a target to reduce the prevalence of HCV infection in Scotland from around 35 000 to 5000 or less over the next 10 years, will be approved by the Scottish Government.
Accordingly, Scotland is truly embracing the concept of elimination and, because of its action plan investment, will be in an outstanding position to deliver.
| Portugal
The success of Portugal in effectively advancing its national agenda on HCV treatment illustrates many of the fiscal, political This effort has been associated with a 73% reduction in the incidence of HCC, a 92.5% reduction in the need for liver transplantation due to hepatitis C and a 93.2% reduction in development of cirrhosis. Thus, it is estimated that the lifelong healthcare costs was reduced by >270 million euros in total, or >30 000 euros per patient.
| The Netherlands
The Netherlands demonstrated the effectiveness of harm reduction strategies towards PWID. The Dutch harm reduction approach builds on programmes that started in the late 1970s with providing methadone in combination with social-medical care and needleexchange facilities aiming to reduce drug users' risk to get infected with blood borne viruses. The approach, probably in combination with demographic changes in the PWID population led to an impressive reduction of blood-borne infection diseases in this population. 48 According to the Amsterdam Cohort Studies among people who use drugs, the incidence of HCV among PWΙD has decreased dramatically since 1986 to nearly zero. 49 However, studies in the Netherlands show an increase in HCV incidence among HIV-positive MSM. 50, 51 Current policy in the Netherlands is to provide prevention, screening, linkage to care, treatment, social welfare and participation for all groups affected by HCV and HBV.
| CON CLUS IONS: EUROPE AN UNION AND NATI ONAL SUPP ORT FOR THE ELIMINATI ON OF VIR AL HEPATITIS IN EUROPE
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Despite the well-documented need, HBV and HCV have struggled to become recognized as public health priorities in Europe. In contrast, HIV has been significantly reduced in terms of incidence in
Europe and serves as a model for promoting access, cooperation and partnership when faced with an outbreak of infectious disease.
Increasingly, EU member states are developing national plans on viral hepatitis. In addition, surveillance is being scaled up with successes in prevention of all infections related to the healthcare setting and, in some member states, successes in access to treatment.
However, there is still a lack of reliable data on the disease burden and on accessibility to DAAs in many member states. There is an urgent need to raise awareness and promote a better understanding of the epidemic to facilitate tailored policies, collaboration and sharing of best practices. Improving EU national policies related to HBV and HCV is a priority for treating and eventually eliminating these diseases.
In facing this challenge, member states count on the support of the ECDC. The ECDC works with member states to provide information, share good practices, help build capacity and provide scientific advice. The organization coordinates HBV and HCV surveillance programmes across EU/European Economic Area countries, maintains a network of European scientific experts, supports countries in prevalence estimates and provides risk estimates taking into account the characteristics of European populations. As noted, an elimination strategy can only be successful with a focus on PWID as a key risk group. 55 The ECDC directly provides evidence-based guidance and technical support with a focus on key populations. As with any other policy area, the active participation of affected individuals and communities in the development of responses in design, implementation and evaluation is the most effective way to ensure that responses fit the needs of patients. In addition to the difficulty in prevention and screening, the cost of treatment of HCV continues to be a major obstacle to European efforts to eliminate the disease. Countries will spend a considerable proportion of their health budgets on costs related to HCV, whether treating the disease or treating liver-related associated diseases, which are costs that already accrue to the health system. Thus, HCV treatment is an investment that can be recovered in future through health savings. However, the issue of political viability of making such an investment is still present in EU countries.
Currently scientific breakthroughs have made eliminating HCV a possibility, with the potential to save lives and lead to a significant savings in societal and economic costs. The specific challenges of HCV require holistic, people-centred, health system-wide approaches to disease awareness, prevention and integrated care and treatment with all stakeholders combining their diverse skills and resources in a unified response. 
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